Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

Pacira Pharma (PCRX) Misses Q4 EPS by 3c

February 28, 2023 8:13 AM EST

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $172 million versus the consensus estimate of $178.59 million.

Today the company is providing full-year 2023 financial guidance as follows:

EXPAREL net product... More